Gregory T. Lucier Buys 2,000 Shares of Catalent Inc (NYSE:CTLT) Stock

Catalent Inc (NYSE:CTLT) Director Gregory T. Lucier bought 2,000 shares of Catalent stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $60.45 per share, with a total value of $120,900.00.

Catalent stock opened at $60.45 on Friday. Catalent Inc has a twelve month low of $39.09 and a twelve month high of $68.78. The firm has a 50 day moving average price of $59.20 and a 200-day moving average price of $53.71. The company has a market capitalization of $8.73 billion, a P/E ratio of 71.96, a P/E/G ratio of 2.58 and a beta of 1.70. The company has a quick ratio of 1.60, a current ratio of 1.98 and a debt-to-equity ratio of 1.65.

Catalent (NYSE:CTLT) last released its earnings results on Monday, February 3rd. The company reported $0.45 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.39 by $0.06. Catalent had a net margin of 5.44% and a return on equity of 15.21%. The firm had revenue of $721.40 million during the quarter, compared to the consensus estimate of $700.81 million. During the same period in the prior year, the firm earned $0.45 EPS. The company’s revenue was up 15.8% compared to the same quarter last year. Equities analysts expect that Catalent Inc will post 1.78 EPS for the current fiscal year.

CTLT has been the subject of a number of research reports. Robert W. Baird reissued an “outperform” rating and set a $67.00 target price (up from $60.00) on shares of Catalent in a research report on Tuesday, February 4th. Morgan Stanley increased their target price on shares of Catalent from $64.00 to $67.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Stephens increased their target price on shares of Catalent from $65.00 to $75.00 and gave the company an “overweight” rating in a research report on Monday, January 27th. Finally, Zacks Investment Research raised shares of Catalent from a “sell” rating to a “hold” rating in a research report on Monday, February 3rd. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $62.43.

Several institutional investors have recently added to or reduced their stakes in the company. Huntington National Bank purchased a new stake in shares of Catalent during the 4th quarter valued at approximately $32,000. Squar Milner Financial Services LLC lifted its stake in shares of Catalent by 173.4% during the 4th quarter. Squar Milner Financial Services LLC now owns 659 shares of the company’s stock valued at $37,000 after buying an additional 418 shares in the last quarter. Evoke Wealth LLC purchased a new stake in shares of Catalent during the 3rd quarter valued at approximately $42,000. Quest Capital Management Inc. ADV purchased a new stake in shares of Catalent during the 3rd quarter valued at approximately $53,000. Finally, Exchange Traded Concepts LLC purchased a new stake in shares of Catalent during the 4th quarter valued at approximately $90,000.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Featured Article: Monthly Dividend Stocks Can Provide Solid Income

Insider Buying and Selling by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.